Cooperative Agreement U27DD001153

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant of $275,000 awarded to Xtract Medical Inc. aims to develop and demonstrate the feasibility of a novel catheter-based system for improved removal of blood clots during mechanical thrombectomy procedures to treat venous thromboembolism (VTE). The proposed system is designed to effectively remove large blood clots while minimizing damage to blood vessels and reducing complications such as...

This Project Grant award of $151,523 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The principal investigator will use novel RNA therapy, delivered via lipid nanoparticles, to selectively reduce circulating fibrinogen levels in rodent and swine models of thrombosis. The goal is to provide...

This Project Grant award of $3,007,209 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the role of Gab2-MALT1-mediated cell signaling in venous thrombogenesis. The funded project aims to: 1) Examine the molecular mechanisms by which the signaling adapter protein Gab2 mediates thromboinflammatory signaling in endothelial cells; 2) Determine the impact of endothelial Gab2-MALT1 signaling on...

This $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to engineer hemostatic red blood cells (T-RBCs) for the treatment of acute non-compressible hemorrhage. The primary objectives are to: 1) engineer T-RBCs that can bind to collagen and fibrin, 2) test the ability of the T-RBCs to enhance clot formation and stability in vitro, and 3) evaluate the circulation time, clot binding, and...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $723,084 to the University of Colorado-Denver to investigate the role of the PAR1/IL-17 signaling axis in the development and progression of chronic thromboembolic pulmonary hypertension (CTEPH). The research aims to determine how this signaling pathway contributes to abnormal cellular phenotypes in chronic thrombus, the initiation and progression of CTEPH,...

This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project titled "Functional Fibrinolysis, Thromboinflammation and VTE Risk for Ventilated Children." The $198,720 award to The Johns Hopkins University, with a project period from January 1, 2025 to December 31, 2029, aims to: Determine the impact of invasive mechanical ventilation intensity on...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $601,677 to the University of Massachusetts (UMass) from May 1, 2025 to February 28, 2029. The research aims to characterize the formation and biological properties of immune complexes composed of platelet factor 4 (PF4) and antibodies that trigger a rare but dangerous side effect known as vaccine-induced immune thrombotic...

The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $790,738 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Circulatech LLC to develop and evaluate the Thoraflush, a proactive clot-preventing cardiac chest tube. The project aims to optimize the Thoraflush's efficacy in maintaining drainage patency using an in vitro mediastinum blood coagulation model, and then assess its performance in an in vivo porcine model...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $445,708 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Brigham & Women's Hospital Inc. The grant aims to define the role of platelet ABO(H) blood group antigens in hemostasis and thrombosis. The research project will investigate how ABO(H) antigens on platelet membrane glycoproteins impact platelet binding to von Willebrand factor and identify the specific platelet glycoproteins that carry...

This $243,000 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) aims to advance patient-centered decision making for older adults with venous thromboembolism (VTE). The primary objectives are to: 1) engage stakeholders to identify core components of individualized VTE treatment decision-making for older adults, 2) use existing data sources to describe the presentation, treatment, and outcomes of VTE in older adult cohorts, and 3) develop and validate a...